Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Total Current Liabilities (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Total Current Liabilities for 6 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities rose 36.45% to $6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 36.45% increase, with the full-year FY2024 number at $3.7 million, up 8.58% from a year prior.
  • Total Current Liabilities was $6.7 million for Q3 2025 at Inhibikase Therapeutics, down from $8.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $8.8 million in Q2 2025 to a low of $1.9 million in Q2 2021.
  • A 5-year average of $4.2 million and a median of $3.7 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: dropped 14.67% in 2023, then skyrocketed 137.53% in 2025.
  • Inhibikase Therapeutics' Total Current Liabilities stood at $4.1 million in 2021, then dropped by 8.85% to $3.7 million in 2022, then fell by 6.95% to $3.4 million in 2023, then grew by 8.58% to $3.7 million in 2024, then skyrocketed by 79.35% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Total Current Liabilities are $6.7 million (Q3 2025), $8.8 million (Q2 2025), and $8.6 million (Q1 2025).